BOSTON & BASEL, Switzerland–(BUSINESS WIRE)–Swiss Rockets AG and Alloy Therapeutics, Inc. today announced the signing of a Master Research Agreement (MRA) establishing a multi-target collaboration to discover and develop next-generation radioligand therapeutics (RLTs) for oncology. The collaboration will be executed through Swiss Rockets’ radiotherapeutics subsidiary, Torpedo Pharmaceuticals AG.

Read more here.